重组骨形态发生蛋白2、碱性成纤维细胞生长因子共转染骨髓间充质干细胞复合纳米羟基磷灰石／重组类人胶原基／聚乳酸复合支架材料支架修复桡骨缺损研究  

Repair of critical-sized bone defect by a novel bone bioengineering construct after co-transfection of recombinant human bone morphogenetic protein-2 and basic fibroblast growth factor into bone marrow stem cells and combination with nano-hydroxyapatite/recombinant human-like collagen/ polylactic acid scaffold

作　　者：郝伟[1] 姜明 王新[1] 周东生[3] 

机构地区：[1]青岛大学医学院附属烟台毓璜顶医院创伤骨科,烟台264000 [2]解放军107医院口腔科 [3]山东大学附属省立医院

出　　处：《中华实验外科杂志》2013年第5期1016-1019,F0003,F0004,共6页Chinese Journal of Experimental Surgery

基　　金：基金项目：烟台市科技发展计划资助项目（2011209）

摘　　要：目的探讨重组人骨形态发生蛋白2（rhBMP-2）、碱性成纤维细胞生长因子（bFGF）双基凶共转染兔骨髓间充质干细胞（BMSCs）复合纳米羟基磷灰石／重组类人胶原基／聚乳酸复合支架材料（nHA／RHLC／PLA）支架构建新型骨组织工程复合体用于修复自体桡骨缺损。方法首先构建兔1．5cm桡骨缺损模型，将体外培养BMSCs经基因转染后与nH_A／RHLC／PLA支架复合构建骨组织T程复合体。分别设立：双基因rhBMP-2和bFGF转染组（A组）、单基因转染组（rhBMP-2：B组；bFGF：C组）、末干预组（D组）、空白材料组（E组）。将各组移植于骨缺损部位，同时设立空白缺损组（F组）作为对照，于术后6、12周取材，行影像学及组织学定性、半定量分析。结果术后6周，A组有明显新骨形成，成骨面积比例为（47．24±4．37）％，高于B组的（28．24±2．35）％、C组的（13．46±2．27）％（P〈0．05），D、E组无明显骨化现象。术后12周，A组骨断端连续性恢复，髓腔冉通，成骨面积比例为（96．84±2．28）％；B组骨断端连续性恢复但髓腔尚未完全再通，成骨面积比例（92．24±1．75）％；C组成骨面积比例（24．73±2．01）％，D组可见少量成骨，E组无骨化现象，C、D、E组骨缺损均未修复，A组明显高于其他组（P〈0．05）。结论采用rhBMP-2及bFGF双基凶转染BMSCs并与nHA／RHLC／PLA支架复合构建新型骨组织工程复合体，具有较理想的骨缺损修复潜能。Objective To repair a 1.5 cm critical-sized rabbit bone defect model by a novel bone bioengineering construct after co-transfection of recombinant human bone morphogenetic protein-2 （rhBMP-2） and basic fibroblast growth factor （bFGF） into bone marrow stem cells （BMSCs） and combination with nano-hydroxyapatite/recombinant human-like collagen/polylactic acid （nHA/RHLC/PLA） scaffold. Methods A 1.5 cm critical-sized bone defect model was created. BMSCs after gene transfeetion were combined with nHA/RHLC/PLA scaffolds to fabricate various biocomposites. Six groups were established： rhBMP-2- bFGF/BMSCs/nHA/RHLC/PLA （A）, rhBMP-2/BMSCs/nHA/RHLC/PLA （B）, bFGF/BMSCs/nHA/ RHLC/PLA （C） , BMSCs/nHA/RHLC/PLA （ D）, nHA/RHLC/PLA （E） and untreated bone defect group （F）. At 6th and 12th week postoperation, the samples were harvested and subjected to radiographic and histologic analyses. Results At 6th week after transplantation, obvious new bone tissue was formed in group A with bone area of （47.24 ± 4. 37 ） %, significantly greater than in group B [ （28.24 ± 2. 35 ） % ] and group C [ （ 13.46 ± 2. 27 ） % ] （ P 〈 0. 05 ）. No bone formation was observed in groups D and E. Twelve weeks later, bone integrity was restored and medullary cavity recanalized in group A with bone area of （ 96.84 ± 2. 28 ） % ; bone integrity was restored but medullary cavity was not recanalized yet in group B with bone area of （ 92. 24 ± 1.75 ） % ; slightly enhanced bone tissue formation was seen in group C [ （24.73 ±2. 01 ）% ] and few new bone tissue was found in group D; no bone tissue was formed in group E. The therapeutic effect for bone defect in group A was superior to other groups （ P 〈 0. 05 ）, and the bone defect in groups C, D and E was not repaired. Conclusion A new bone tissue engineering biocomposite by the combination of nHA/RHLC/PLA and BMSCs after double-transfection of rhBMP-2 and bFGF can produce apparently bone tissue in orthotopic site, which provides a ne

关 键 词：重组骨形态发生蛋白2 碱性成纤维细胞生长因子 骨髓间充质干细胞 骨缺损 

分 类 号：R318.08[医药卫生—生物医学工程]